TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions.

Humans Neoplasms / drug therapy Oncogene Proteins, Fusion Protein Kinase Inhibitors / therapeutic use
Fusion Larotrectinib NTRK

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 17 09 2019
revised: 26 05 2020
accepted: 27 05 2020
pubmed: 11 6 2020
medline: 16 7 2020
entrez: 11 6 2020
Statut: ppublish

Résumé

Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.

Identifiants

DOI: 10.1016/j.critrevonc.2020.103011 PMID: 32521311
pubmed: 32521311
pii: S1040-8428(20)30149-9
doi: 10.1016/j.critrevonc.2020.103011
pii:
doi:

Substances chimiques

Oncogene Proteins, Fusion 0
Protein Kinase Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103011

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Giandomenico Roviello (G)

Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. Electronic address: giandomenicoroviello@hotmail.it.

Alberto D'Angelo (A)

Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, United Kingdom.

Marianna Sciortino (M)

Diaceutics PLC, 55 Adelaide Street, Belfast, BT2 8FE, UK.

Enrico Mini (E)

Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.

Stefania Nobili (S)

Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.

Francesco De Logu (F)

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Daniela Massi (D)

Section of Anatomic Pathology, Department of Health Sciences, University of Florence and Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › TRK fusion positive cancers: From first...
questionsmedicales.fr › Tumeurs › TRK fusion positive cancers: From first...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines de fusion oncogènes › TRK fusion positive cancers: From first...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › TRK fusion positive cancers: From first...